Authors
Jaya M Mehta, JoAnn E Manson
Published in
Current atherosclerosis reports. Volume 28. Issue 1. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
This review examines the cardiometabolic changes that occur during the menopausal transition (MT), emphasizing how hormonal fluctuations may contribute to the development of adverse cardiovascular disease (CVD) risk factors. It identifies gaps in evidence regarding safe and effective treatments for cardiometabolic risk reduction during the MT.
The MT is characterized by hormonal shifts driving adverse changes in body composition, lipid profiles, vascular function, and metabolic regulation. These alterations are associated with accelerated progression of cardiovascular risk factors and may contribute to the increase in CVD risk observed after menopause. Growing evidence suggests that the MT represents a distinct period of cardiometabolic vulnerability and provides an opportunity for early risk identification and prevention. Lifestyle and behavioral modifications, as well as control of blood pressure, lipids, and other established risk factors, are the foundations of risk-reducing management and treatment. Early cardiometabolic risk assessment and individualized, lifestyle -centered management are essential to optimize cardiovascular outcomes during the MT. Further research is needed to clarify therapeutic strategies for this critical window in women's cardiometabolic health.
PMID:
43049825
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0